

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **Zylox-Tonbridge Medical Technology Co., Ltd.**

**歸創通橋醫療科技股份有限公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 2190)**

### **VOLUNTARY ANNOUNCEMENT COMPLETION OF PATIENT ENROLLMENT FOR THE FLOW DIVERTER CLINICAL TRIAL**

This announcement is made by Zylox-Tonbridge Medical Technology Co., Ltd (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business updates of the Group.

The Company is pleased to announce that on November 29, 2021, the last patient enrollment was completed for the “Efficacy and Safety Study of Flow Diverter (血流導向裝置) for the Intravascular Treatment of Intracranial Aneurysms (Prospective, Multi-center, Single-arm Objective Performance Criteria Clinical Trial)” (the “**Study**”). The Study has achieved significant progress in less than five months since the first enrollment initiated in July this year.

As stated in the prospectus issued by the Company dated June 22, 2021, the China Intracranial Aneurysm Interventional Device Market has great potential for development. The number of intracranial aneurysm interventional procedures in China increased from 30.6 thousand in 2015 to 60.0 thousand in 2019 and is estimated to further increase to 443.7 thousand in 2030, at a CAGR of 19.9% from 2019 to 2030.

The flow diverter is a revolutionary product for the treatment of intracranial aneurysms, and is gradually becoming one of the most important approaches for the treatment of various intracranial aneurysms in recent years. Our flow diverter is made of nitinol with the advantages including full visualisation and good adhesiveness, which can better isolate the aneurysms and reconstruct the diseased vessel, while avoiding the occurrence of penetrating occlusion with better safety.

**The Company may not ultimately be able to successfully develop and market the flow diverter. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.**

By order of the Board  
**Zylox-Tonbridge Medical Technology Co., Ltd.**  
**Dr. Jonathon Zhong Zhao**  
*Chairman and Executive Director*

Hong Kong, November 29, 2021

*As of the date of this announcement, the Board comprises Dr. Jonathon Zhong Zhao, Mr. Yang Xie and Dr. Zheng Li as executive Directors, Mr. Stephen Hui Wang, Dr. Hai Lu and Dr. Steven Dasong Wang as non-executive Directors, and Dr. Jian Ji, Mr. Hongze Liang and Ms. Yun Qiu as independent non-executive Directors.*